Pfizer Inc. (PFE) EV/FCF Ratio: 22.50x
Is Pfizer Inc.’s EV/FCF ratio high or low?
Pfizer Inc.'s EV/FCF ratio of 22.50x is in line with its 5-year average of 21.37x, around the middle of its 5-year range (9.45x–49.81x).
As of Thursday, June 11, 2026. 13.82% above its 12-month average of 19.77x.
PFE EV/FCF Ratio Chart
PFE Average EV/FCF Ratio Chart
PFE Current vs Average EV/FCF Ratio Chart
PFE EV/FCF Ratio Metrics
EV/FCF RATIO
22.50x
EV/FCF RATIO AVG TTM
19.77x
EV/FCF RATIO AVG 3Y
27.32x
EV/FCF RATIO AVG 5Y
21.37x
EV/FCF RATIO AVG 10Y
20.51x
EV/FCF RATIO AVG 15Y
18.31x
EV/FCF RATIO AVG 20Y
17.11x
CURRENT VS TTM AVG
+13.82%
CURRENT VS 3Y AVG
-17.64%
CURRENT VS 5Y AVG
+5.27%
CURRENT VS 10Y AVG
+9.71%
CURRENT VS 15Y AVG
+22.89%
CURRENT VS 20Y AVG
+31.50%
PFE Competitors' EV/FCF Ratio
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pfizer Inc. (PFE) | $149.61B | 22.50x | 19.77x | 27.32x | 21.37x |
| Intuitive Surgical, Inc. (ISRG) | $144.79B | 51.59x | 79.78x | 160.45x | 125.16x |
| Abbott Laboratories (ABT) | $155.75B | 24.89x | 30.96x | 34.90x | 31.02x |
| Gilead Sciences, Inc. (GILD) | $156.35B | 16.31x | 18.52x | 16.04x | 14.51x |
| Danaher Corporation (DHR) | $127.91B | 27.10x | 31.97x | 32.30x | 30.49x |
| CVS Health Corporation (CVS) | $126.81B | 26.26x | 27.81x | 26.94x | 21.12x |
| Thermo Fisher Scientific Inc. (TMO) | $176.21B | 32.15x | 35.74x | 34.61x | 34.76x |
| Bristol-Myers Squibb Company (BMY) | $116.13B | 12.69x | 10.44x | 11.39x | 12.31x |
| Amgen Inc. (AMGN) | $188.37B | 26.64x | 22.34x | 24.94x | 22.49x |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.59B | 29.44x | 32.26x | 28.31x | 25.04x |
Cash Flow Valuation Comparison
EV/FCF
22.5x
P/FCF
15.9x
FCF Yield
6.30%
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
- EV/FCF accounts for debt and cash through enterprise value
- P/FCF only considers equity value
- EV/FCF can be compared across companies with different debt levels
- Both measure how the market values cash generation
Pfizer Inc. EV/FCF Ratio Formula & Definition
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Pfizer Inc. EV/FCF Ratio FAQ
- What is the EV/FCF ratio for Pfizer Inc. (PFE)?
- The EV/FCF ratio for PFE stock is 22.50x.
- Is Pfizer Inc.'s EV/FCF ratio high or low?
- Pfizer Inc.'s EV/FCF ratio of 22.50x is in line with its 5-year average of 21.37x, around the middle of its 5-year range (9.45x–49.81x).
- What is the TTM average EV/FCF ratio for Pfizer Inc. (PFE)?
- The TTM average EV/FCF ratio for PFE stock is 19.77x.
- What is the 3Y average EV/FCF ratio for Pfizer Inc. (PFE)?
- The 3Y average EV/FCF ratio for PFE stock is 27.32x.
- What is the 5Y average EV/FCF ratio for Pfizer Inc. (PFE)?
- The 5Y average EV/FCF ratio for PFE stock is 21.37x.
- What is the 10Y average EV/FCF ratio for Pfizer Inc. (PFE)?
- The 10Y average EV/FCF ratio for PFE stock is 20.51x.
- What is the 15Y average EV/FCF ratio for Pfizer Inc. (PFE)?
- The 15Y average EV/FCF ratio for PFE stock is 18.31x.
- What is the 20Y average EV/FCF ratio for Pfizer Inc. (PFE)?
- The 20Y average EV/FCF ratio for PFE stock is 17.11x.
Pfizer Inc. EV/FCF Ratio History
| DATE | EV/FCF RATIO |
|---|---|
| 2026-06-11 | 22.50x |
| 2026-06-10 | 22.09x |
| 2026-06-09 | 22.15x |
| 2026-06-08 | 22.10x |
| 2026-06-05 | 22.35x |
| 2026-06-04 | 22.14x |
| 2026-06-03 | 21.93x |
| 2026-06-02 | 22.06x |
| 2026-06-01 | 22.10x |
| 2026-05-29 | 22.44x |
| 2026-05-28 | 22.41x |
| 2026-05-27 | 22.45x |
| 2026-05-26 | 22.24x |
| 2026-05-22 | 22.27x |
| 2026-05-21 | 22.30x |
| 2026-05-20 | 22.20x |
| 2026-05-19 | 22.12x |
| 2026-05-18 | 21.92x |
| 2026-05-15 | 21.92x |
| 2026-05-14 | 22.18x |
| 2026-05-13 | 22.30x |
| 2026-05-12 | 22.25x |
| 2026-05-11 | 22.21x |
| 2026-05-08 | 22.13x |
| 2026-05-07 | 22.62x |
| 2026-05-06 | 22.65x |
| 2026-05-05 | 22.60x |
| 2026-05-04 | 23.78x |
| 2026-05-01 | 23.80x |
| 2026-04-30 | 24.03x |
| 2026-04-29 | 23.75x |
| 2026-04-28 | 23.89x |
| 2026-04-27 | 24.09x |
| 2026-04-24 | 24.22x |
| 2026-04-23 | 24.01x |
| 2026-04-22 | 24.09x |
| 2026-04-21 | 24.41x |
| 2026-04-20 | 24.54x |
| 2026-04-17 | 24.57x |
| 2026-04-16 | 24.36x |
| 2026-04-15 | 24.34x |
| 2026-04-14 | 24.29x |
| 2026-04-13 | 24.43x |
| 2026-04-10 | 24.17x |
| 2026-04-09 | 24.36x |
| 2026-04-08 | 24.51x |
| 2026-04-07 | 24.28x |
| 2026-04-06 | 24.74x |
| 2026-04-02 | 25.04x |
| 2026-04-01 | 25.19x |
| 2026-03-31 | 24.89x |
| 2026-03-30 | 24.70x |
| 2026-03-27 | 24.24x |
| 2026-03-26 | 24.57x |
| 2026-03-25 | 24.39x |
| 2026-03-24 | 24.19x |
| 2026-03-23 | 24.07x |
| 2026-03-20 | 24.20x |
| 2026-03-19 | 24.47x |
| 2026-03-18 | 24.42x |
| 2026-03-17 | 24.50x |
| 2026-03-16 | 23.97x |
| 2026-03-13 | 23.95x |
| 2026-03-12 | 24.13x |
| 2026-03-11 | 24.41x |
| 2026-03-10 | 24.32x |
| 2026-03-09 | 24.10x |
| 2026-03-06 | 24.25x |
| 2026-03-05 | 23.97x |
| 2026-03-04 | 23.98x |
| 2026-03-03 | 23.95x |
| 2026-03-02 | 24.38x |
| 2026-02-27 | 24.62x |
| 2026-02-26 | 24.28x |
| 2026-02-25 | 20.74x |
| 2026-02-24 | 20.76x |
| 2026-02-23 | 20.72x |
| 2026-02-20 | 20.49x |
| 2026-02-19 | 20.61x |
| 2026-02-18 | 20.89x |
| 2026-02-17 | 20.89x |
| 2026-02-13 | 21.01x |
| 2026-02-12 | 20.95x |
| 2026-02-11 | 21.09x |
| 2026-02-10 | 21.02x |
| 2026-02-09 | 20.71x |
| 2026-02-06 | 20.81x |
| 2026-02-05 | 20.41x |
| 2026-02-04 | 20.57x |
| 2026-02-03 | 20.01x |
| 2026-02-02 | 20.50x |
| 2026-01-30 | 20.38x |
| 2026-01-29 | 20.19x |
| 2026-01-28 | 20.06x |
| 2026-01-27 | 20.41x |
| 2026-01-26 | 20.07x |
| 2026-01-23 | 19.94x |
| 2026-01-22 | 20.19x |
| 2026-01-21 | 20.08x |
| 2026-01-20 | 19.87x |
| 2026-01-16 | 19.94x |
| 2026-01-15 | 20.08x |
| 2026-01-14 | 19.90x |
| 2026-01-13 | 19.67x |
| 2026-01-12 | 19.73x |
| 2026-01-09 | 19.85x |
| 2026-01-08 | 19.75x |
| 2026-01-07 | 19.74x |
| 2026-01-06 | 19.82x |
| 2026-01-05 | 19.68x |
| 2026-01-02 | 19.68x |
| 2025-12-31 | 19.53x |
| 2025-12-30 | 19.58x |
| 2025-12-29 | 19.59x |
| 2025-12-26 | 19.64x |
| 2025-12-24 | 19.60x |
| 2025-12-23 | 19.52x |
| 2025-12-22 | 19.70x |
| 2025-12-19 | 19.69x |
| 2025-12-18 | 19.61x |
| 2025-12-17 | 19.61x |
| 2025-12-16 | 19.88x |
| 2025-12-15 | 20.37x |
| 2025-12-12 | 20.05x |
| 2025-12-11 | 20.03x |
| 2025-12-10 | 20.02x |
| 2025-12-09 | 19.77x |
| 2025-12-08 | 20.01x |
| 2025-12-05 | 20.15x |
| 2025-12-04 | 19.97x |
| 2025-12-03 | 19.90x |
| 2025-12-02 | 19.67x |
| 2025-12-01 | 19.73x |
| 2025-11-28 | 19.99x |
| 2025-11-26 | 19.98x |
| 2025-11-25 | 19.98x |
| 2025-11-24 | 19.71x |
| 2025-11-21 | 19.61x |
| 2025-11-20 | 19.26x |
| 2025-11-19 | 19.52x |
| 2025-11-18 | 19.83x |
| 2025-11-17 | 19.63x |
| 2025-11-14 | 19.62x |
| 2025-11-13 | 20.02x |
| 2025-11-12 | 20.06x |
| 2025-11-11 | 19.87x |
| 2025-11-10 | 19.25x |
| 2025-11-07 | 19.27x |
| 2025-11-06 | 19.50x |
| 2025-11-05 | 19.37x |
| 2025-11-04 | 19.20x |
| 2025-11-03 | 16.15x |
| 2025-10-31 | 16.15x |
| 2025-10-30 | 15.98x |
| 2025-10-29 | 15.98x |
| 2025-10-28 | 16.08x |
| 2025-10-27 | 16.20x |
| 2025-10-24 | 16.20x |
| 2025-10-23 | 16.15x |
| 2025-10-22 | 16.18x |
| 2025-10-21 | 16.24x |
| 2025-10-20 | 16.16x |
| 2025-10-17 | 16.08x |
| 2025-10-16 | 15.95x |
| 2025-10-15 | 16.03x |
| 2025-10-14 | 16.09x |
| 2025-10-13 | 16.18x |
| 2025-10-10 | 16.20x |
| 2025-10-09 | 16.42x |
| 2025-10-08 | 16.62x |
| 2025-10-07 | 16.89x |
| 2025-10-06 | 16.96x |
| 2025-10-03 | 17.39x |
| 2025-10-02 | 17.26x |
| 2025-10-01 | 17.32x |
| 2025-09-30 | 16.53x |
| 2025-09-29 | 15.78x |
| 2025-09-26 | 15.74x |
| 2025-09-25 | 15.66x |
| 2025-09-24 | 15.89x |
| 2025-09-23 | 15.91x |
| 2025-09-22 | 15.87x |
| 2025-09-19 | 15.86x |
| 2025-09-18 | 15.92x |
| 2025-09-17 | 15.87x |
| 2025-09-16 | 15.80x |
| 2025-09-15 | 15.83x |
| 2025-09-12 | 15.79x |
| 2025-09-11 | 16.24x |
| 2025-09-10 | 16.11x |
| 2025-09-09 | 16.17x |
| 2025-09-08 | 16.10x |
| 2025-09-05 | 16.25x |
| 2025-09-04 | 16.09x |
| 2025-09-03 | 16.21x |
| 2025-09-02 | 16.30x |
| 2025-08-29 | 16.20x |
| 2025-08-28 | 16.12x |
| 2025-08-27 | 16.34x |
| 2025-08-26 | 16.27x |
| 2025-08-25 | 16.37x |
| 2025-08-22 | 16.71x |
| 2025-08-21 | 16.65x |
| 2025-08-20 | 16.48x |
| 2025-08-19 | 16.45x |
| 2025-08-18 | 16.34x |
| 2025-08-15 | 16.37x |
| 2025-08-14 | 16.36x |
| 2025-08-13 | 16.38x |
| 2025-08-12 | 16.15x |
| 2025-08-11 | 16.11x |
| 2025-08-08 | 16.11x |
| 2025-08-07 | 15.95x |
| 2025-08-06 | 15.81x |
| 2025-08-05 | 16.19x |
| 2025-08-04 | 17.31x |
| 2025-08-01 | 17.29x |
| 2025-07-31 | 17.19x |
| 2025-07-30 | 17.45x |
| 2025-07-29 | 17.70x |
| 2025-07-28 | 17.71x |
| 2025-07-25 | 17.95x |
| 2025-07-24 | 18.24x |
| 2025-07-23 | 18.24x |
| 2025-07-22 | 18.13x |
| 2025-07-21 | 17.68x |
| 2025-07-18 | 17.79x |
| 2025-07-17 | 17.84x |
| 2025-07-16 | 17.86x |
| 2025-07-15 | 17.86x |
| 2025-07-14 | 18.24x |
| 2025-07-11 | 18.39x |
| 2025-07-10 | 18.45x |
| 2025-07-09 | 18.34x |
| 2025-07-08 | 18.37x |
| 2025-07-07 | 18.18x |
| 2025-07-03 | 18.25x |
| 2025-07-02 | 18.22x |
| 2025-07-01 | 18.08x |
| 2025-06-30 | 17.67x |
| 2025-06-27 | 17.65x |
| 2025-06-26 | 17.67x |
| 2025-06-25 | 17.68x |
| 2025-06-24 | 17.71x |
| 2025-06-23 | 17.56x |
| 2025-06-20 | 17.53x |
| 2025-06-18 | 17.49x |
| 2025-06-17 | 17.55x |
| 2025-06-16 | 17.75x |
| 2025-06-13 | 17.82x |
| 2025-06-12 | 17.98x |
| 2025-06-11 | 17.79x |
| 2025-06-10 | 17.70x |
| 2025-06-09 | 17.53x |
| 2025-06-06 | 17.22x |
| 2025-06-05 | 17.10x |
| 2025-06-04 | 17.24x |
| 2025-06-03 | 17.22x |
| 2025-06-02 | 17.27x |
| 2025-05-30 | 17.29x |
Showing the most recent 260 of 5,032 data points. The chart above shows the full history.
Related Metrics
About Pfizer Inc.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Albert Bourla